Munzanga yanhasi, kufutisa kwazova dambudziko rehutano pasi rose, uye kubuda kweRetatrutideinopa tariro itsva kune varwere vari kunetseka nehuremu hwakawandisa. Retatrutide akatatu receptor agonistkunangaGLP-1R, GIPR, uye GCGR. Iyi yakasarudzika yakawanda-yakananga synergistic meshini inoratidza inoshamisa kugona kwekureruka.
Mechanistically, Retatrutide inoshandaGLP-1 receptors, iyo inokurudzira kugadzirwa kwe insulini, inodzvinyirira kusunungurwa kweglucagon, uye kunonoka kubuda kwegastric, nokudaro kunowedzera kuguta uye kuderedza kudya kwekudya. Kuitwa kwayo kweGIP receptorsinowedzera kunatsiridza insulin senitivity, inogadzirisa lipid metabolism, uye inoshanda synergistically neGLP-1 kukwidziridza mhedzisiro inoderedza uremu. Zvinotonyanya kukosha, activation yayo yeglucagon receptors (GCGR)inowedzera kushandiswa kwesimba, inowedzera hepatic gluconeogenesis inhibition, uye inoderedza kuunganidza mafuta echiropa-pamwe chete, nzira idzi dzinobatsira pakurasikirwa kukuru.
Mumakiriniki ekuedzwa, kurasikirwa kwehuremu kweRetatrutide kwave kunoshamisa. Mune 48-vhiki Phase 2 yekiriniki yekudzidza, vatori vechikamu vanogamuchira vhiki nevhiki 12 mg dose yeRetatrutide vakarasikirwa neavhareji ye24.2% yehuremu hwemuviri wavo-mugumisiro unodarika mishonga yakawanda yekurasikirwa kwehuremu uye inosvika pakubudirira kwekuvhiyiwa kwebariatric. Uyezve, kurasikirwa kwehuremu kunoramba kuchivandudza nekufamba kwenguva; byvhiki 72, avhareji yekuderedza uremu yakasvika inenge28%.
Kupfuura simba rayo rekudzikisa uremu, Retatrutide inoratidzawo chivimbiso chikuru mukuvandudza matambudziko ane chekuita nekufutisa. Inogona kuderedza BP, kuvandudza lipid profiles, kuderedza triglyceride mazinga, uye kupa kudzivirira kwemoyo-kuunza.hutano hwakakwanakuvanhu vanorarama nekufutisa.
Nguva yekutumira: Jul-16-2025